tau 284 has been researched along with Allergic Conjunctivitis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharatam, PV; Chakraborti, AK; Giri, S; Sahu, A; Singh, DK; Singh, S; Wani, AA | 1 |
| Ayyappanavar, S; Gangasagara, SB; Jayanthi, CR; Kumar, K; Mittal, P; Preethi, B; Rathod, BLS; Sridhar, S | 1 |
| Bielory, L; Duttachoudhury, S; McMunn, A | 1 |
| Abelson, MB; Gomes, PJ; Gow, JA; McNamara, TR; Torkildsen, GL; Williams, JI | 2 |
| Atsumi, I; Fujii, A; Iemura, M; Kida, T; Sakai, O; Sakaki, H; Wada, T | 1 |
| Abelson, MB; Bergmann, MT; Gomes, PJ; Gow, JA; Macejko, TT; McNamara, TR; Williams, JI | 1 |
| Gow, JA; Klier, SM; McCue, SL; McNamara, TR; Salapatek, AM; Williams, JI | 1 |
| Abelson, MB; Gomes, PJ; Gow, JA; Kennedy, KS; McNamara, TR; Torkildsen, GL; Williams, JI | 1 |
| Babu, M; Dudeja, I; Dudeja, L; Janakiraman, A; Sane, K | 1 |
2 review(s) available for tau 284 and Allergic Conjunctivitis
| Article | Year |
|---|---|
Bepotastine besilate for the treatment of pruritus.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Clinical Trials as Topic; Conjunctivitis, Allergic; Histamine H1 Antagonists; Humans; Piperidines; Pruritus; Pyridines; Rhinitis, Allergic; Rhinitis, Allergic, Perennial; Urticaria | 2013 |
Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate.
Topics: Animals; Anti-Allergic Agents; Conjunctivitis, Allergic; Disease Models, Animal; Drug Evaluation, Preclinical; Histamine Antagonists; Humans; Mice; Piperidines; Pruritus; Pyridines; Rats | 2010 |
6 trial(s) available for tau 284 and Allergic Conjunctivitis
| Article | Year |
|---|---|
Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Topics: Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Double-Blind Method; Humans; Imidazoles; Olopatadine Hydrochloride; Ophthalmic Solutions; Piperidines; Prospective Studies; Pyridines; Treatment Outcome | 2021 |
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen cha
Topics: Administration, Topical; Adolescent; Adult; Aged; Allergens; Anti-Allergic Agents; Child; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Prospective Studies; Pruritus; Pyridines; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2009 |
Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Child; Conjunctiva; Conjunctivitis, Allergic; Double-Blind Method; Female; Humans; Hyperemia; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Prospective Studies; Pyridines; Treatment Outcome; Visual Acuity | 2010 |
Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
Topics: Adult; Allergens; Conjunctivitis, Allergic; Double-Blind Method; Female; Histamine Antagonists; Humans; Immunization; Male; Middle Aged; Nasal Obstruction; Ophthalmic Solutions; Piperidines; Pyridines | 2010 |
Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Conjunctiva; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperemia; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Prospective Studies; Pruritus; Pyridines; Time Factors; Young Adult | 2011 |
Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Benzazepines; Child; Conjunctiva; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Histamine H1 Antagonists; Humans; Imidazoles; Male; Olopatadine Hydrochloride; Ophthalmic Solutions; Piperidines; Prospective Studies; Pyridines; Single-Blind Method; Treatment Outcome; Young Adult | 2019 |
2 other study(ies) available for tau 284 and Allergic Conjunctivitis
| Article | Year |
|---|---|
Characterization of Photodegradation Products of Bepotastine Besilate and In Silico Evaluation of Their Physicochemical, Absorption, Distribution, Metabolism, Excretion and Toxicity Properties.
Topics: Computer Simulation; Conjunctivitis, Allergic; Gas Chromatography-Mass Spectrometry; Humans; Photolysis; Piperidines; Pyridines | 2020 |
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Topics: Animals; Capillary Permeability; Cells, Cultured; Chemotaxis, Leukocyte; Conjunctiva; Conjunctivitis, Allergic; Disease Models, Animal; Dose-Response Relationship, Drug; Eosinophils; Guinea Pigs; Histamine; Histamine H1 Antagonists; Histamine Release; Leukotriene B4; Male; Mast Cells; Ovalbumin; Peritoneal Cavity; Piperidines; Platelet Activating Factor; Pyridines; Rats; Rats, Wistar | 2010 |